Fresh funding has been awarded by the GHIT Fund to EVI and its partners from Nagasaki University, German biopharmaceutical firm Mologen AG, Charité - Universitätsmedizin Berlin and the London School of Hygiene and Tropical Medicine (LSHTM) to support the completion of the preclinical development of a novel leishmaniasis vaccine candidate and for preparing the conduct of a future Phase I clinical trial.

The EVI 2016 Annual Report provides an overview of all the activities EVI was involved in during 2016.  We hope it will be an interesting read for you.

After four years of collaborative research activities towards the development of a broadly reactive influenza vaccine, the European Commission-funded project EDUFLUVAC will be concluded by the end of October 2017. The EDUFLUVAC partners met for the final project meeting on 09-10 October in Brussels, Belgium to review the results generated and plan for future activities. 

Open Call for Vaccine Development Services

The European Commission Research and Innovation Directorate published a report it had commissioned to evaluate the role and impact of the European Union’s (EU) Research Framework Programme activities in the field of Poverty-Related and Neglected Diseases (PRNDs).

VAC2VAC is pleased to announce that one year after its start it has already created enough interest to have the Medicines Evaluation Board (MEB), a regulatory agency and an independent administrative body residing under the Government of the Netherlands, joining its membership.

During the first year of the VAC2VAC project ample of process has been made. Here you can find a two page summary of the progress.

The European Commission (EC), in the context of the Horizon 2020 Framework Programme, commits significant funding to TRANSVAC2, a European vaccine research and development (R&D) infrastructure.